OncoMatch/Clinical Trials/NCT06644937

Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Is NCT06644937 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies TACE combined with Acoradine for hepatocellular carcinoma (hcc).

Phase 2/3RecruitingZhujiang HospitalNCT06644937Data as of May 2026

Treatment: TACE combined with Acoradine — To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage BCLC STAGE B (BCLC)

Grade: low differentiation (histopathologic)

BCLC stage B (> 3 tumors, regardless of size or number, at least one of which is > 3 cm in diameter); single tumor ≥5 cm in diameter; intraoperative or postoperative pathological findings of vascular invasion (including microvascular invasion and VP1/VP2 portal vein invasion); histopathologic grade of low differentiation; capsular invasion or loss with unclear border; direct invasion of adjacent organs

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Must have received: surgery (R0 resection) — curative

R0 resection was performed within 4 to 8 weeks before recruitment

Cannot have received: anti-tumor therapy for hepatocellular carcinoma (systemic or local)

Exception: 1-2 prophylactic TACE or HAIC 4-8 weeks after radical therapy

None of the patients had received anti-tumor therapy for hepatocellular carcinoma, including systemic therapy and local therapy (except for 1-2 prophylactic TACE or HAIC 4-8 weeks after radical therapy)

Lab requirements

Liver function

child-pugh score of 5-6

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify